March 12, 2019 / 10:29 PM / 2 months ago

BUZZ-Aeterna Zentaris: Rises on strategic review plans

** U.S.-listed shares of Canadian drug developer up 6.5 pct at $3.93 after the bell

** Aeterna hires investment bank Company of Torreya to review strategic options, including sale of the company

** Potential transactions include opportunities to license macimorelin, AEZS’ product for the diagnosis of adult growth hormone deficiency, outside of U.S. and Canada

** Co says there is no defined timeline for the review

** Company has a market cap of about $61 mln (Reporting by Tamara Mathias in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below